期刊文献+

Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy, primary results of study CU 1005 被引量:5

Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy, primary results of study CU 1005
原文传递
导出
摘要 The role of adjuvant hormonal therapy and optimized regimens for high-risk localized prostate cancer after radical prostatectomy remains controversial. Herein, the clinical trial CU 1005 prospectively evaluated two regimens of maximum androgen blockage or bicalutamide 150 mg daily as immediate adjuvant therapy for high-risk localized prostate cancer. Overall, 209 consecutive patients were recruited in this study, 107 of whom received 9 months of adjuvant maximum androgen blockage, whereas 102 received 9 months of adjuvant bicalutamide 150 mg. The median postoperative follow-up time was 27.0 months. The primary endpoint was biochemical recurrence. Of the 209 patients, 59 patients developed biochemical recurrence. There was no difference between the two groups with respect to clinical characteristics, including age, pretreatment prostate-specific antigen, Gleason score, surgical margin status, or pathological stages. The maximum androgen blockage group experienced longer biochemical recurrence-free survival (P = 0.004) compared with the bicalutamide 150 mg group. Side-effects in the two groups were similar and could be moderately tolerated in all patients. In conclusion, immediate, 9-month maximum androgen blockage should be considered as an alternative to bicalutamide 150 mg as adjuvant treatment for high-risk localized prostate cancer patients after radical prostatectomy. The role of adjuvant hormonal therapy and optimized regimens for high-risk localized prostate cancer after radical prostatectomy remains controversial. Herein, the clinical trial CU 1005 prospectively evaluated two regimens of maximum androgen blockage or bicalutamide 150 mg daily as immediate adjuvant therapy for high-risk localized prostate cancer. Overall, 209 consecutive patients were recruited in this study, 107 of whom received 9 months of adjuvant maximum androgen blockage, whereas 102 received 9 months of adjuvant bicalutamide 150 mg. The median postoperative follow-up time was 27.0 months. The primary endpoint was biochemical recurrence. Of the 209 patients, 59 patients developed biochemical recurrence. There was no difference between the two groups with respect to clinical characteristics, including age, pretreatment prostate-specific antigen, Gleason score, surgical margin status, or pathological stages. The maximum androgen blockage group experienced longer biochemical recurrence-free survival (P = 0.004) compared with the bicalutamide 150 mg group. Side-effects in the two groups were similar and could be moderately tolerated in all patients. In conclusion, immediate, 9-month maximum androgen blockage should be considered as an alternative to bicalutamide 150 mg as adjuvant treatment for high-risk localized prostate cancer patients after radical prostatectomy.
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2016年第3期452-455,I0010,共5页 亚洲男性学杂志(英文版)
关键词 ADJUVANT BICALUTAMIDE HIGH-RISK maximum androgen blockage prostate cancer radical prostatectomy adjuvant bicalutamide high-risk maximum androgen blockage prostate cancer radical prostatectomy
  • 相关文献

参考文献2

二级参考文献9

  • 1Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004 ; 22: 2141-9.
  • 2D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.
  • 3Bastian P J, Gonzalgo ML, Aronson W J, Terris MK, Kane CJ et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 2006: 107: 1265-72.
  • 4Zietman AL, Shipley WU. Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. Int J Radiat Oncol Biol Phys 1997; 37: 245-6.
  • 5Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer,J Clin Oncol 2008; 26: 2497-504.
  • 6Bolla M, de Reijke TM, van Tienhoven G, van den Bergh AC, Oddens Jet al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-27.
  • 7Denham JW, Steigler A, Lamb DS, Joseph D, Turner Set al. Short-term neoadjuvant androgen depri- vation and radiotherapy for locally advanced prostate cancer: lO-year data from the TROG 96.01 randomized trial. Lancet Oncol 2011; 12: 451-9.
  • 8Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommen- dations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol BioJ Phys 1999; 44: 789-99.
  • 9Bittner N, Merrick GS, Wallner KE, Butler WM. Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer. Oncology 2008; 22: 995-1017.

共引文献8

同被引文献24

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部